admin

The value of decreased plasma gelsolin levels in patients with systemic lupus erythematosus and rheumatoid arthritis in diagnosis and disease activity evaluation

YL Hu*, H Li*, WH Li, HX Meng, YZ Fan, WJ Li, YT Ji, H Zhao, L Zhang, XM Jin, FM ZhangFM ZhangOctober 11, 2013 Abstract Plasma gelsolin, the extracellular gelsolin isoform, circulates in the blood of healthy individuals at a concentration of 200 ± 50 mg/l and plays important roles in the extracellular actin-scavenging system during tissue damage. Decreased plasma gelsolin levels have been observed in many …

The value of decreased plasma gelsolin levels in patients with systemic lupus erythematosus and rheumatoid arthritis in diagnosis and disease activity evaluation Read More »

Modifications of cellular responses to lysophosphatidic acid and platelet-activating factor by plasma gelsolin.

Osborn TM1, Dahlgren C, Hartwig JH, Stossel TP.April, 2007 Abstract Gelsolin is a highly conserved intracellular actin-binding protein with an extracellular isoform, plasma gelsolin (pGSN). Blood concentrations of pGSN decrease in response to diverse tissue injuries. Depletion of pGSN to critical levels precedes and often predicts complications of injuries such as lung permeability changes and death. Administration of …

Modifications of cellular responses to lysophosphatidic acid and platelet-activating factor by plasma gelsolin. Read More »

Plasma gelsolin and circulating actin correlate with hemodialysis mortality.

Lee PS1, Sampath K, Karumanchi SA, Tamez H, Bhan I, Isakova T, Gutierrez OM, Wolf M, Chang Y, Stossel TP, Thadhani R.May, 2009 Abstract Plasma gelsolin (pGSN) binds actin and bioactive mediators to localize inflammation. Low pGSN correlates with adverse outcomes in acute injury, whereas administration of recombinant pGSN reduces mortality in experimental sepsis. We found that mean pGSN levels of 150 patients randomly selected …

Plasma gelsolin and circulating actin correlate with hemodialysis mortality. Read More »

Relationship of plasma gelsolin levels to outcomes in critically ill surgical patients.

Lee PS1, Drager LR, StosselTP, Moore FD, Rogers SO.March, 2006 Abstract OBJECTIVE:To examine the relationship between plasma gelsolin levels and mortality following surgery or trauma.BACKGROUND:Few simple predictive diagnostic tests are available to predict mortality following surgery or trauma. We hypothesize that plasma concentrations of gelsolin, a protein that responds to injured tissue, might be a predictor of patient outcomes.METHODS:We …

Relationship of plasma gelsolin levels to outcomes in critically ill surgical patients. Read More »

Decreased levels of the gelsolin plasma isoform in patients with rheumatoid arthritis.

Osborn TM1, Verdrengh M, Stossel TP, Tarkowski A, Bokarewa M.September, 2008 Abstract INTRODUCTION: Gelsolin is an intracellular actin-binding protein involved in cell shape changes, cell motility, and apoptosis. An extracellular gelsolin isoform, plasma gelsolin circulates in the blood of healthy individuals at a concentration of 200 +/- 50 mg/L and has been suggested to be a key component of …

Decreased levels of the gelsolin plasma isoform in patients with rheumatoid arthritis. Read More »

Plasma gelsolin is a marker and therapeutic agent in animal sepsis.

Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Lee PS1, Waxman AB, Cotich KL, Chung SW, Perrella MA, Stossel TP. Abstract OBJECTIVE: Plasma gelsolin is a circulating actin-binding protein that serves a protective role against tissue injuries. Depletion of plasma gelsolin in systemic inflammation may contribute to adverse outcomes. We examined the role of plasma gelsolin in …

Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Read More »

Extracellular gelsolin binds lipoteichoic acid and modulates cellular response to proinflammatory bacterial wall components.

Bucki R1, Byfield FJ, Kulakowska A, McCormick ME, Drozdowski W, Namiot Z, Hartung T, Janmey PA.October 1, 2008 Abstract The various functions of gelsolin in extracellular compartments are not yet clearly defined but include actin scavenging and antiinflammatory effects. Gelsolin was recently reported to bind endotoxin (LPS) from various Gram-negative bacteria with high affinity. In this study we investigate whether gelsolin also …

Extracellular gelsolin binds lipoteichoic acid and modulates cellular response to proinflammatory bacterial wall components. Read More »

October, 2019: BioAegis Therapeutics Named New Jersey’s Most Valuable Venture-Backed Company Led by a Woman

MORRISTOWN, N.J., Oct. 22, 2019 (BIOAEGIS THERAPEUTICS) — BioAegis Therapeutics was recently recognized by PitchBook as the most valuable venture-backed company in New Jersey led by a female entrepreneur. PitchBook is a financial data and software company that provides transparency to capital markets to help professionals discover and execute opportunities. BioAegis Therapeutics’ accolade was based …

October, 2019: BioAegis Therapeutics Named New Jersey’s Most Valuable Venture-Backed Company Led by a Woman Read More »

July 1, 2015: BioAegis Therapeutics Collaboration with Harvard School of Public Health Discovers Plasma Gelsolin Boosts the Immune Response to Pathogens

Dr. Lester Kobzik, Professor of Medicine, Harvard T.H. Chan School of Public Health Publishes: Plasma gelsolin improves lung host defense against pneumonia by enhancing macrophage NOS3 function. This major plasma gelsolin advancement was published in May in Journal of American Physiology—Lung, Cellular and Molecular Physiology. Read article here.

April 15, 2015: BioAegis Therapeutics Completes Initial $8 Million Convertible Note: Round Oversubscribed

Company Enters into Collaborative Research Agreement with NIAID and Company to Run Phase 2a/b Trials in EU BioAegis Therapeutics Inc., a privately held biotechnology company commercializing plasma gelsolin (pGSN), an endogenous human protein that simultaneously modulates inflammation and boosts immune function announced that its recently closed convertible note round was oversubscribed by investors. Read article …

April 15, 2015: BioAegis Therapeutics Completes Initial $8 Million Convertible Note: Round Oversubscribed Read More »